Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisocabtagene Maraleucel, Nivolumab, and Ibrutinib in Richter's Transformation
NCT05672173Phase 2Active, not recruiting
- Sponsor
- City of Hope
- Start
- Jun 2023
- Primary completion
- Aug 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of lisocabtagene maraleucel in Richter's transformation (RT), sponsored by City of Hope. Started Jun 2023; status: active, not recruiting.
02
Drugs
lisocabtagene maraleucel
03
Conditions
Richter's transformation (RT)
Beyond the preview
Go deeper on NCT05672173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05672173.